Consensus Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2025-12-12 pm EST			5-day change	1st Jan Change
222.26 ^USD	-1.65%		-1.59%	+13.10%

Dec. 11	Certara, Inc. Announces Board Changes	CI
Dec. 11	Certara, Inc. Announces CEO Changes	CI

Evolution of the Average Target: Iqvia Holdings Inc.

Evolution of the Target Price: Iqvia Holdings Inc.

Changes in Analyst Recommendations: Iqvia Holdings Inc.

3f570aaacabb914a74ed70.tfOiZxALRmpT_6tr4cn6eLwPDlESMUuEVASZ29Bm9Zs.jLiaMFdzGSkfp_0EoougHshuVAVrBT7WImrTkbQLkvOGtPsfY2cuEmSb4g~e24dd89672fc6a322968979e51881b33

Analysts' recommendations: Iqvia Holdings Inc.

Dec. 02	Morgan Stanley Raises Price Target on IQVIA Holdings to $265 From $250, Keeps Overweight Rating	MT
Dec. 02	Jefferies Adjusts Price Target on IQVIA Holdings to $270 From $255, Maintains Buy Rating	MT
Dec. 01	HSBC Adjusts Price Target on IQVIA Holdings Inc to $270 From $250, Maintains Buy Rating	MT
Nov. 13	BMO Capital Initiates IQVIA Holdings at Outperform With $260 Price Target	MT
Nov. 03	TD Cowen Downgrades IQVIA Holdings to Hold From Buy, Adjusts Price Target to $215 From $206	MT
Oct. 31	Mizuho Securities Adjusts IQVIA Price Target to $250 From $225	MT
Oct. 30	Rothschild & Co Redburn Adjusts IQVIA Holdings Price Target to $254 From $214	MT
Oct. 29	Jefferies Adjusts Price Target on IQVIA Holdings Inc to $255 From $225, Maintains Buy Rating	MT
Oct. 29	JPMorgan Lifts Price Target on IQVIA to $255 From $177, Maintains Overweight Rating	MT
Oct. 29	HSBC Adjusts Price Target on IQVIA Holdings Inc to $250 From $235, Maintains Buy Rating	MT
Oct. 29	UBS Adjusts Price Target on IQVIA to $250 From $225, Maintains Buy Rating	MT
Oct. 29	Truist Raises Price Target on IQVIA Holdings to $265 From $235, Keeps Buy Rating	MT
Oct. 29	Stifel Nicolaus Adjusts IQVIA Price Target to $254 From $234, Maintains Buy Rating	MT
Oct. 29	Evercore ISI Adjusts IQVIA Price Target to $250 From $240, Maintains Outperform Rating	MT
Oct. 29	Citigroup Adjusts IQVIA Price Target to $230 From $200, Maintains Neutral Rating	MT
Oct. 29	Leerink Partners Adjusts IQVIA Price Target to $256 From $232, Maintains Outperform Rating	MT
Oct. 29	Stephens Adjusts IQVIA Price Target to $250 From $220, Maintains Overweight Rating	MT
Oct. 29	Baird Upgrades IQVIA Holdings to Outperform From Neutral, Adjusts Price Target to $258 From $224	MT
Oct. 28	Citigroup Raises Price Target on IQVIA to $230 From $200	MT
Oct. 20	BofA Adjusts Price Target on IQVIA Holdings to $230 From $215	MT
Oct. 16	Deutsche Bank Adjusts Price Target on IQVIA to $235 From $220, Maintains Buy Rating	MT
Oct. 13	Baird Adjusts IQVIA Holdings Price Target to $224 From $206, Maintains Neutral Rating	MT
Oct. 09	IQVIA Shares Higher After HSBC Upgrade	MT
Oct. 09	HSBC Upgrades IQVIA Holdings to Buy From Hold, Adjusts Price Target to $235 From $195	MT
Oct. 09	Analysts recommendations: Datadog, Alphabet, AMD, Elevance Health, Tesla…

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	IQVIA HOLDINGS INC.					+10.63%
	LONZA GROUP AG					+28.92%
	BEONE MEDICINES AG					+25.15%
	CELLTRION, INC.					+19.69%
	MEDPACE HOLDINGS, INC.					-4.87%
	REVOLUTION MEDICINES, INC.					+3.36%
	ICON PUBLIC LIMITED COMPANY					+8.56%
	TEMPUS AI, INC.					+23.77%
	ASCENDIS PHARMA A/S					+23.13%
	IONIS PHARMACEUTICALS, INC.					+8.6%
	Average					+14.69%
	Weighted average by Cap.					+17.23%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

222.26USD

Average target price

250.00USD

Spread / Average Target

+12.48%

High Price Target

270.00USD

Spread / Highest target

+21.48%

Low Price Target

200.00USD

Spread / Lowest Target

-10.02%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Morgan Stanley
Jefferies & Co.
HSBC
BMO Capital
TD Cowen
Mizuho Securities
Rothschild & Co Redburn
JPMorgan Chase
UBS
Truist Securities
Stifel Nicolaus
Evercore ISI
Citigroup
Leerink Partners
Stephens Inc.
Baird
BofA Securities
Deutsche Bank Securities
Barclays
Argus
Redburn Atlantic
Goldman Sachs
BTIG
Nephron Research
RBC Capital Markets
Guggenheim
Wells Fargo Securities
Cowen
Credit Suisse
SVB Securities LLC
Piper Sandler
KeyBanc Capital Markets